These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 33542205)

  • 1. Expanding the role of proteasome homeostasis in Parkinson's disease: beyond protein breakdown.
    Bi M; Du X; Jiao Q; Chen X; Jiang H
    Cell Death Dis; 2021 Feb; 12(2):154. PubMed ID: 33542205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of the Immunoproteasome Subunit Lmp7 Links Proteostasis and Immunity in α-Synuclein Aggregation Disorders.
    Ugras S; Daniels MJ; Fazelinia H; Gould NS; Yocum AK; Luk KC; Luna E; Ding H; McKennan C; Seeholzer S; Martinez D; Evans P; Brown D; Duda JE; Ischiropoulos H
    EBioMedicine; 2018 May; 31():307-319. PubMed ID: 29759483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial Failure of Proteostasis Systems Counteracting TDP-43 Aggregates in Neurodegenerative Diseases.
    Cascella R; Fani G; Bigi A; Chiti F; Cecchi C
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein degradation pathways in Parkinson's disease: curse or blessing.
    Ebrahimi-Fakhari D; Wahlster L; McLean PJ
    Acta Neuropathol; 2012 Aug; 124(2):153-72. PubMed ID: 22744791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological proteins in Parkinson's disease: focus on the proteasome.
    Snyder H; Wolozin B
    J Mol Neurosci; 2004; 24(3):425-42. PubMed ID: 15655264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome Activation to Combat Proteotoxicity.
    Jones CL; Tepe JJ
    Molecules; 2019 Aug; 24(15):. PubMed ID: 31387243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with Lewy bodies.
    Barrachina M; Castaño E; Dalfó E; Maes T; Buesa C; Ferrer I
    Neurobiol Dis; 2006 May; 22(2):265-73. PubMed ID: 16380264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bassoon inhibits proteasome activity via interaction with PSMB4.
    Montenegro-Venegas C; Fienko S; Anni D; Pina-Fernández E; Frischknecht R; Fejtova A
    Cell Mol Life Sci; 2021 Feb; 78(4):1545-1563. PubMed ID: 32651614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders.
    Njomen E; Tepe JJ
    J Med Chem; 2019 Jul; 62(14):6469-6481. PubMed ID: 30839208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic analysis of protein homeostasis and aggregation.
    Laskowska E; Kuczyńska-Wiśnik D; Lipińska B
    J Proteomics; 2019 Apr; 198():98-112. PubMed ID: 30529741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteostasis in Parkinson's disease: Recent development and possible implication in diagnosis and therapeutics.
    Kulkarni A; Preeti K; Tryphena KP; Srivastava S; Singh SB; Khatri DK
    Ageing Res Rev; 2023 Feb; 84():101816. PubMed ID: 36481490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered proteasomal function in sporadic Parkinson's disease.
    McNaught KS; Belizaire R; Isacson O; Jenner P; Olanow CW
    Exp Neurol; 2003 Jan; 179(1):38-46. PubMed ID: 12504866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The disturbance of protein synthesis/degradation homeostasis is a common trait of age-related neurodegenerative disorders.
    Di Domenico F; Lanzillotta C
    Adv Protein Chem Struct Biol; 2022; 132():49-87. PubMed ID: 36088079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptides that activate the 20S proteasome by gate opening increased oxidized protein removal and reduced protein aggregation.
    Dal Vechio FH; Cerqueira F; Augusto O; Lopes R; Demasi M
    Free Radic Biol Med; 2014 Feb; 67():304-13. PubMed ID: 24291399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degradation of Tyrosine Hydroxylase by the Ubiquitin-Proteasome System in the Pathogenesis of Parkinson's Disease and Dopa-Responsive Dystonia.
    Kawahata I; Fukunaga K
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases.
    Pajares M; Cuadrado A; Rojo AI
    Redox Biol; 2017 Apr; 11():543-553. PubMed ID: 28104575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubiquitin-dependent and independent roles of SUMO in proteostasis.
    Liebelt F; Vertegaal AC
    Am J Physiol Cell Physiol; 2016 Aug; 311(2):C284-96. PubMed ID: 27335169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of intracellular protein degradation pathways in Parkinson's disease and therapeutics.
    K A; Mishra A; Singh S
    J Neurosci Res; 2022 Oct; 100(10):1834-1844. PubMed ID: 35819247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases.
    Ross CA; Pickart CM
    Trends Cell Biol; 2004 Dec; 14(12):703-11. PubMed ID: 15564047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson's disease models through PKA activation.
    Chen JY; Zhu Q; Cai CZ; Luo HB; Lu JH
    Phytomedicine; 2022 Jul; 101():154125. PubMed ID: 35525236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.